A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

Key facts

Sponsor

Heronova Pharmaceuticals

Intervention

DC05F01(drug)

Enrollment

60 target

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Study locations (2)

• The Fisrt Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
• Hunan Cancer Hospital, Changsha, Hunan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell carcinoma of the ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07424547
  Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
  Conjupro Biotherapeutics, Inc.
• RECRUITINGPHASE1NCT07444814
  Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
  Whitehawk Therapeutics, Inc.
• RECRUITINGPHASE1NCT06774963
  A Phase 1 Study of LNCB74 in Advanced Solid Tumors
  NextCure, Inc.
• ACTIVE NOT RECRUITINGPHASE1NCT06253520
  Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
  National Cancer Institute (NCI)
• RECRUITINGPHASE1NCT05104515
  First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
  Oxford Vacmedix UK Ltd.
• RECRUITINGPHASE2NCT04602377
  Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
  ARCAGY/ GINECO GROUP
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02734004
  A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
  AstraZeneca

See all trials for Small cell carcinoma of the ovary →